<?xml version="1.0" encoding="utf-8"?>
<chapter id="c0010" version="5.2" docsubtype="chp" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd"
         xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink">
    <info>
        <ce:pii>B978-0-7234-3863-2.00002-7</ce:pii>
        <ce:doi>10.1016/B978-0-7234-3863-2.00002-7</ce:doi>
        <ce:isbn>978-0-7234-3863-2</ce:isbn>
        <ce:copyright type="full-transfer" year="2015">Elsevier Ltd</ce:copyright>
    </info>
    <ce:floats>
        <ce:figure id="f0010">
            <ce:label>Fig. 2.1</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0010">Mechanism of action of antidepressants at the synaptic cleft
                </ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-01-9780723436362" id="lk0010"/>
        </ce:figure>
        <ce:figure id="f0015">
            <ce:label>Fig. 2.2</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0015">Classification and pharmacodynamics of the antidepressants</ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-02-9780723436362" id="lk0015"/>
        </ce:figure>
        <ce:figure id="f0020">
            <ce:label>Fig. 2.3</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0020">Common side-effects of the SSRIs</ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-03-9780723436362" id="lk0020"/>
        </ce:figure>
        <ce:figure id="f0025">
            <ce:label>Fig. 2.4</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0025">Common side-effects of tricyclic antidepressants</ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-04-9780723436362" id="lk0025"/>
        </ce:figure>
        <ce:figure id="f0030">
            <ce:label>Fig. 2.5</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0030">Drugs and food that may precipitate a hypertensive crisis in combination
                    with MAOIs
                </ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-05-9780723436362" id="lk0030"/>
        </ce:figure>
        <ce:figure id="f0035">
            <ce:label>Fig. 2.6</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0035">Side-effects and signs of toxicity of lithium</ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-06-9780723436362" id="lk0035"/>
        </ce:figure>
        <ce:figure id="f0040">
            <ce:label>Fig. 2.7</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0040">Side-effects of valproate, carbamazepine and lamotrigine</ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-07-9780723436362" id="lk0040"/>
        </ce:figure>
        <ce:figure id="f0045">
            <ce:label>Fig. 2.8</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0045">Commonly used antipsychotics</ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-08-9780723436362" id="lk0045"/>
        </ce:figure>
        <ce:figure id="f0050">
            <ce:label>Fig. 2.9</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0050">The clinical effects and side-effects of conventional antipsychotics
                </ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-09-9780723436362" id="lk0050"/>
        </ce:figure>
        <ce:figure id="f0055">
            <ce:label>Fig. 2.10</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0055">Antipsychotic-induced extrapyramidal side-effects and treatment
                </ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-10-9780723436362" id="lk0055"/>
        </ce:figure>
        <ce:figure id="f0060">
            <ce:label>Fig. 2.11</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0060">Distinguishing neuroleptic malignant syndrome from serotonin syndrome
                </ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-11-9780723436362" id="lk0060"/>
        </ce:figure>
        <ce:figure id="f0065">
            <ce:label>Fig. 2.12</ce:label>
            <ce:caption>
                <ce:simple-para id="sp0065">Classification of the benzodiazepines and Z drugs</ce:simple-para>
            </ce:caption>
            <ce:link locator="f02-12-9780723436362" id="lk0065"/>
        </ce:figure>
    </ce:floats>
    <ce:label>2</ce:label>
    <ce:title>Pharmacological therapy and electroconvulsive therapy</ce:title>
    <objectives>
        <ce:section-title id="st0010">Objectives</ce:section-title>
        <ce:para id="p0010">After this chapter you should have an understanding of:
            <ce:list id="l0010">
                <ce:list-item id="u0010">
                    <ce:label>•</ce:label>
                    <ce:para id="p0015">The history, classification, mechanism of action, side-effects, indications and
                        contraindications of:
                        <ce:list id="l0130">
                            <ce:list-item id="u0015">
                                <ce:label>•</ce:label>
                                <ce:para id="p0020">Antidepressants</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0020">
                                <ce:label>•</ce:label>
                                <ce:para id="p0025">Mood stabilizers</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0025">
                                <ce:label>•</ce:label>
                                <ce:para id="p0030">Antipsychotics</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0030">
                                <ce:label>•</ce:label>
                                <ce:para id="p0035">Anxiolytics</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0035">
                                <ce:label>•</ce:label>
                                <ce:para id="p0040">Electroconvulsive therapy</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:list-item>
            </ce:list>
        </ce:para>
    </objectives>
    <ce:sections>
        <ce:para id="p0045">Psychotropic (mind-altering) medication can be divided into the following groups:
            <ce:list id="l0015">
                <ce:list-item id="u0040">
                    <ce:label>•</ce:label>
                    <ce:para id="p0050">Antidepressants</ce:para>
                </ce:list-item>
                <ce:list-item id="u0045">
                    <ce:label>•</ce:label>
                    <ce:para id="p0055">Mood stabilizers</ce:para>
                </ce:list-item>
                <ce:list-item id="u0050">
                    <ce:label>•</ce:label>
                    <ce:para id="p0060">Antipsychotics</ce:para>
                </ce:list-item>
                <ce:list-item id="u0055">
                    <ce:label>•</ce:label>
                    <ce:para id="p0065">Anxiolytics and hypnotics</ce:para>
                </ce:list-item>
                <ce:list-item id="u0060">
                    <ce:label>•</ce:label>
                    <ce:para id="p0070">Other</ce:para>
                </ce:list-item>
            </ce:list>
        </ce:para>
        <ce:para id="p0075">Despite its simplicity, this arbitrary method of grouping drugs is flawed because many drugs
            from one class are now used to treat disorders in another class, e.g. antidepressants are first line
            therapies for many anxiety disorders and some antipsychotics also have mood stabilizing and antidepressant
            effects.
        </ce:para>
        <ce:section id="s0010">
            <ce:section-title id="st0015">ANTIDEPRESSANTS</ce:section-title>
            <ce:section id="s0015">
                <ce:section-title id="st0020">History</ce:section-title>
                <ce:para id="p0080">Antidepressants were first used in the late 1950s, with the appearance of the
                    tricyclic antidepressant (TCA) imipramine and the monoamine oxidase inhibitor (MAOI) phenelzine.
                    Research into TCAs throughout the 1960s and 1970s developed many more tricyclic agents and related
                    compounds. A major development in the late 1980s was the arrival of the first selective serotonin
                    reuptake inhibitor (SSRI), fluoxetine (Prozac®). There has since been considerable expansion of the
                    SSRI class, and development of antidepressants with other mechanisms such as mirtazapine.
                </ce:para>
            </ce:section>
            <ce:section id="s0020">
                <ce:section-title id="st0025">Classification and mechanism of action</ce:section-title>
                <ce:para id="p0085">At present we classify antidepressants according to their pharmacological actions,
                    as we do not as yet have an adequate explanation as to what exactly makes antidepressants work.
                    Although there are at least eight different classes of antidepressants, their common action is to
                    elevate the levels of one or more monoamine neurotransmitters in the synaptic cleft.
                    <ce:cross-ref refid="f0010">Figure 2.1</ce:cross-ref>
                    <ce:float-anchor refid="f0010"/>
                    illustrates the mechanism of action of antidepressants at synapses. The latest research has focused
                    on monoamine neurotransmitter activation of ‘second messenger’ signal transduction mechanisms. This
                    results in the production of transcription factors that lead to the activation of genes controlling
                    the expression of downstream targets such as ‘brain-derived neurotrophic factor’ (BDNF). BDNF is
                    neuroprotective and might be one key target of antidepressant action.
                    <ce:cross-ref refid="f0015">Figure 2.2</ce:cross-ref>
                    <ce:float-anchor refid="f0015"/>
                    summarizes the classification and pharmacodynamics of the important antidepressants.
                    <ce:display>
                        <ce:textbox role="alt0" id="b0010">
                            <ce:textbox-head>
                                <ce:title>HINTS AND TIPS</ce:title>
                            </ce:textbox-head>
                            <ce:textbox-body>
                                <ce:sections>
                                    <ce:para id="p0090">Certain tricyclic antidepressants (e.g. clomipramine) have more
                                        potency for blocking the serotonin reuptake pump; whereas others are more
                                        selective for noradrenaline (norepinephrine) (e.g. desipramine, nortriptyline).
                                        Most, however, block both noradrenaline (norepinephrine) and serotonin reuptake.
                                    </ce:para>
                                </ce:sections>
                            </ce:textbox-body>
                        </ce:textbox>
                    </ce:display>
                </ce:para>
            </ce:section>
            <ce:section id="s0025">
                <ce:section-title id="st0030">Indications</ce:section-title>
                <ce:para id="p0095">SSRIs are used in the treatment of:
                    <ce:list id="l0020">
                        <ce:list-item id="u0065">
                            <ce:label>•</ce:label>
                            <ce:para id="p0100">Depression – see pages<ce:intra-ref id="ia9200"
                                                                                    xlink:href="pii:B978-0-7234-3863-2.00018-0#s0070">
                                135–136</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0070">
                            <ce:label>•</ce:label>
                            <ce:para id="p0105">Anxiety disorders – see pages<ce:intra-ref id="ia9805"
                                                                                           xlink:href="pii:B978-0-7234-3863-2.00020-9#f0015">
                                149–150</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0075">
                            <ce:label>•</ce:label>
                            <ce:para id="p0110">Obsessive-compulsive disorder – see pages<ce:intra-ref id="ia9910"
                                                                                                       xlink:href="pii:B978-0-7234-3863-2.00020-9#f0015">
                                149–150</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0080">
                            <ce:label>•</ce:label>
                            <ce:para id="p0115">Bulimia nervosa (fluoxetine) – see<ce:intra-ref id="ia9010"
                                                                                                xlink:href="pii:B978-0-7234-3863-2.00023-4#f0015">
                                p. 165</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                    Mirtazapine is used in the treatment of:
                    <ce:list id="l0025">
                        <ce:list-item id="u0085">
                            <ce:label>•</ce:label>
                            <ce:para id="p0125">Depression (particularly where sedation or increased oral intake is
                                desirable).
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                    Tricyclic antidepressants are used in the treatment of:
                    <ce:list id="l0030">
                        <ce:list-item id="u0090">
                            <ce:label>•</ce:label>
                            <ce:para id="p0135">Depression – see pages<ce:intra-ref id="ia9205"
                                                                                    xlink:href="pii:B978-0-7234-3863-2.00018-0#s0070">
                                135–136</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0095">
                            <ce:label>•</ce:label>
                            <ce:para id="p0140">Anxiety disorders – see pages<ce:intra-ref id="ia9820"
                                                                                           xlink:href="pii:B978-0-7234-3863-2.00020-9#f0015">
                                149–150</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0100">
                            <ce:label>•</ce:label>
                            <ce:para id="p0145">Obsessive-compulsive disorder (clomipramine) – see pages<ce:intra-ref
                                    id="ia9130" xlink:href="pii:B978-0-7234-3863-2.00020-9#f0015">149–150</ce:intra-ref>
                                .
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0105">
                            <ce:label>•</ce:label>
                            <ce:para id="p0150">Other: chronic pain, nocturnal enuresis (see<ce:intra-ref id="ia9015"
                                                                                                          xlink:href="pii:B978-0-7234-3863-2.00027-1#s0145">
                                p. 191</ce:intra-ref>), narcolepsy (see<ce:intra-ref id="ia9020"
                                                                                     xlink:href="pii:B978-0-7234-3863-2.00030-1#p0420">
                                p. 204</ce:intra-ref>).
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                    MAOIs are used in the treatment of:
                    <ce:list id="l0035">
                        <ce:list-item id="u0110">
                            <ce:label>•</ce:label>
                            <ce:para id="p0160">Depression (especially atypical depression, characterized by
                                hypersomnia, overeating, anxiety) – see pages<ce:intra-ref id="ia9210"
                                                                                           xlink:href="pii:B978-0-7234-3863-2.00018-0#s0070">
                                    135–136</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0115">
                            <ce:label>•</ce:label>
                            <ce:para id="p0165">Anxiety disorders – see pages<ce:intra-ref id="ia9140"
                                                                                           xlink:href="pii:B978-0-7234-3863-2.00020-9#f0015">
                                149–150</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0120">
                            <ce:label>•</ce:label>
                            <ce:para id="p0170">Other: eating disorders, chronic pain, Parkinson's disease, migraine
                                prophylaxis, tuberculosis.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                </ce:para>
            </ce:section>
            <ce:section id="s0030">
                <ce:section-title id="st0035">Side-effects and contraindications</ce:section-title>
                <ce:section id="s0035">
                    <ce:section-title id="st0040">SSRIs</ce:section-title>
                    <ce:para id="p0175">SSRIs have fewer anticholinergic effects than the TCAs, and are not sedating.
                        The majority of patients find them alerting, so they are prescribed in the morning. Soon after
                        initiation, or when taken at high doses, some patients can feel alerted to the point of
                        agitation/anxiety. This may be associated with an increased risk of suicide, particularly in
                        adolescents. The only SSRI recommended in under 18s is fluoxetine. Due to their low
                        cardiotoxicity, SSRIs are the antidepressant of choice in patients with cardiac disease and in
                        those who are at risk of taking an overdose. However, they do have their own side-effects that
                        may be unacceptable to some patients. These are summarized in
                        <ce:cross-ref refid="f0020">Figure 2.3</ce:cross-ref>
                        <ce:float-anchor refid="f0020"/>. Venlafaxine is a selective serotonin and noradrenaline
                        reuptake inhibitor, which has similar side-effects to SSRIs but they tend to be more severe.
                    </ce:para>
                    <ce:para id="p0180">Contraindications: mania.</ce:para>
                </ce:section>
                <ce:section id="s0040">
                    <ce:section-title id="st0045">Mirtazapine</ce:section-title>
                    <ce:para id="p0185">Mirtazapine is very commonly associated with increased appetite, weight gain,
                        and sedation (via histamine antagonism). These side-effects can be used to advantage in many
                        patients. It is also associated with headache and a dry mouth, and less commonly dizziness,
                        postural hypotension, tremor and peripheral oedema. It has negligible anticholinergic effects.
                    </ce:para>
                    <ce:para id="p0190">Contraindications: mania.</ce:para>
                </ce:section>
                <ce:section id="s0045">
                    <ce:section-title id="st0050">Tricyclic antidepressants</ce:section-title>
                    <ce:para id="p0195">
                        <ce:cross-ref refid="f0025">Figure 2.4</ce:cross-ref>
                        <ce:float-anchor refid="f0025"/>
                        summarizes the common side-effects of the TCAs, most of which are related to the multi-receptor
                        blocking effects of these drugs. The side-effect of sedation can be useful if patients have
                        insomnia. TCAs with prominent sedative effects include amitriptyline and clomipramine. Those
                        with less sedative effects include lofepramine and imipramine. Due to their cardiotoxic effects,
                        TCAs are dangerous in overdose, although lofepramine (a newer TCA) has fewer antimuscarinic
                        effects and so is relatively safer.
                    </ce:para>
                    <ce:para id="p0200">Contraindications: recent myocardial infarction, arrhythmias, severe liver
                        disease, mania and high risk of overdose.
                    </ce:para>
                    <ce:para id="p0205">Trazodone is molecularly similar to tricyclics but clinically quite different.
                        It is a relatively weak antidepressant but a good sedative. It is relatively safe in overdose
                        and has negligible anticholinergic side-effects. It is often used as an adjunctive
                        antidepressant in those receiving a non-sedative primary antidepressant, e.g. an SSRI.
                        <ce:display>
                            <ce:textbox role="alt0" id="b0015">
                                <ce:textbox-head>
                                    <ce:title>HINTS AND TIPS</ce:title>
                                </ce:textbox-head>
                                <ce:textbox-body>
                                    <ce:sections>
                                        <ce:para id="p0210">Antidepressants should be used with caution in patients with
                                            epilepsy, as they tend to lower the seizure threshold.
                                        </ce:para>
                                    </ce:sections>
                                </ce:textbox-body>
                            </ce:textbox>
                        </ce:display>
                    </ce:para>
                </ce:section>
                <ce:section id="s0050">
                    <ce:section-title id="st0055">MAOIs/RIMA</ce:section-title>
                    <ce:para id="p0215">Due to the risk of serious interactions with certain foods and other drugs, the
                        MAOIs have become second line antidepressants. Their inhibition of monoamine oxidase A results
                        in the accumulation of amine neurotransmitters and impairs the metabolism of some amines found
                        in certain drugs (e.g. decongestants) and foodstuffs (e.g. tyramine). Because MAOIs bind
                        irreversibly to monoamine oxidase A and B, amines may accumulate to dangerously high levels,
                        which may precipitate a life-threatening hypertensive crisis. An example of this occurs when the
                        ingestion of dietary tyramine results in a massive release of noradrenaline (norepinephrine)
                        from endogenous stores. This is termed the ‘cheese reaction’ because some mature cheeses
                        typically contain high levels of tyramine. Note that an early warning sign is a throbbing
                        headache.
                        <ce:cross-ref refid="f0030">Figure 2.5</ce:cross-ref>
                        <ce:float-anchor refid="f0030"/>
                        lists the drugs and foodstuffs that should be avoided in patients taking MAOIs.
                    </ce:para>
                    <ce:para id="p0220">The RIMA moclobemide reversibly inhibits monoamine oxidase A. Therefore, the
                        drug will be displaced from the enzyme as amine levels start to increase. So, although there is
                        a small risk of developing a hypertensive crisis if high levels of tyramine are ingested,
                        dietary restrictions are much less onerous.
                    </ce:para>
                    <ce:para id="p0225">When other antidepressants that have a strong serotonergic effect (e.g. SSRIs,
                        clomipramine, imipramine) are administered simultaneously with an MAOI, the risk of developing
                        the potentially lethal ‘serotonin syndrome’ is increased. In common with the neuroleptic
                        malignant syndrome, it is associated with the triad of neuromuscular abnormalities, altered
                        consciousness level and autonomic instability but the two are usually easily distinguished on
                        the basis of the history (see
                        <ce:cross-ref refid="f0060">Fig. 2.11</ce:cross-ref>
                        <ce:float-anchor refid="f0060"/>). Therefore, other antidepressants should not be started for 2
                        weeks after an MAOI has been stopped (3 weeks in the case of clomipramine and imipramine).
                        Conversely, an MAOI should not be started for 2 weeks after the termination of another
                        antidepressant (3 weeks in the case of clomipramine and imipramine; 5 weeks in the case of
                        fluoxetine, because of its long half-life). The coadministration of opiates and an MAOI can also
                        result in the serotonin syndrome. This is because opiates (especially pethidine and tramadol)
                        have some intrinsic serotonin reuptake inhibitory activity.
                    </ce:para>
                    <ce:para id="p0230">MAOIs may have further side-effects similar to the TCAs, including postural
                        hypotension and anticholinergic effects.
                    </ce:para>
                    <ce:para id="p0235">Contraindications (MAOIs): phaeochromocytoma, cerebrovascular disease, hepatic
                        impairment, mania.
                        <ce:display>
                            <ce:textbox role="alt0" id="b0020">
                                <ce:textbox-head>
                                    <ce:title>HINTS AND TIPS</ce:title>
                                </ce:textbox-head>
                                <ce:textbox-body>
                                    <ce:sections>
                                        <ce:para id="p0240">The abrupt withdrawal of any antidepressant may result in a
                                            discontinuation syndrome with symptoms such as gastrointestinal disturbance,
                                            agitation, dizziness, headache, tremor and insomnia. SSRIs with short
                                            half-lives (e.g. paroxetine, sertraline) and venlafaxine are particular
                                            culprits. Therefore, all antidepressants (with the exception of fluoxetine,
                                            which has a long half-life and many active metabolites) should be gradually
                                            tapered down before being withdrawn completely. Although certain
                                            antidepressants may cause a withdrawal syndrome, they do not cause a
                                            dependence syndrome or ‘addiction’ in that patients do not become tolerant
                                            to them or crave them.
                                        </ce:para>
                                    </ce:sections>
                                </ce:textbox-body>
                            </ce:textbox>
                        </ce:display>
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0055">
            <ce:section-title id="st0060">MOOD STABILIZERS</ce:section-title>
            <ce:para id="p0245">These include lithium and the anticonvulsants valproate, carbamazepine and lamotrigine.
                Other anticonvulsants, such as gabapentin, topiramate and vigabatrin, are also being investigated for
                mood stabilizing properties.
            </ce:para>
            <ce:section id="s0060">
                <ce:section-title id="st0065">History</ce:section-title>
                <ce:para id="p0250">In 1949, John Cade discovered that lithium salts caused lethargy when injected into
                    animals, and later reported lithium's antimanic properties in humans. Trials in the 1950s and 1960s
                    led to the drug entering mainstream practice in 1970.
                </ce:para>
                <ce:para id="p0255">Valproate was first recognized as an effective anticonvulsant in 1962. Along with
                    carbamazepine and lamotrigine, it was later shown to be effective in bipolar affective disorder.
                </ce:para>
            </ce:section>
            <ce:section id="s0065">
                <ce:section-title id="st0070">Mechanism of action</ce:section-title>
                <ce:para id="p0260">It is not known how any of the mood stabilizers work. Lithium appears to modulate
                    the neurotransmitter-induced activation of second messenger systems. Valproate and carbamazepine may
                    exert their effect via the GABA system; carbamazepine is a GABA agonist and valproate inhibits GABA
                    transaminase. Lamotrigine reduces neural activation via inhibition of sodium channels.
                </ce:para>
            </ce:section>
            <ce:section id="s0070">
                <ce:section-title id="st0075">Indications</ce:section-title>
                <ce:para id="p0265">Lithium is used in the treatment of:
                    <ce:list id="l0040">
                        <ce:list-item id="u0125">
                            <ce:label>•</ce:label>
                            <ce:para id="p0270">Acute mania – see page<ce:intra-ref id="ia9025"
                                                                                    xlink:href="pii:B978-0-7234-3863-2.00018-0#s0090">
                                137</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0130">
                            <ce:label>•</ce:label>
                            <ce:para id="p0275">Prophylaxis of bipolar affective disorder (prevention of relapse) – see
                                page<ce:intra-ref id="ia9030" xlink:href="pii:B978-0-7234-3863-2.00018-0#s0135">
                                    138</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0135">
                            <ce:label>•</ce:label>
                            <ce:para id="p0280">Treatment-resistant depression (lithium augmentation) – see page
                                <ce:intra-ref id="ia9135" xlink:href="pii:B978-0-7234-3863-2.00018-0#f0025">
                                    136</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0140">
                            <ce:label>•</ce:label>
                            <ce:para id="p0285">Other: adjunct to antipsychotics in schizoaffective disorder and
                                schizophrenia; and aggression/impulsivity – see page
                                <ce:intra-ref id="ia9045" xlink:href="pii:B978-0-7234-3863-2.00019-2#f0015">144
                                </ce:intra-ref>
                                and page<ce:intra-ref id="ia9040" xlink:href="pii:B978-0-7234-3863-2.00022-2#s0040">
                                    161</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                    Valproate is used in the treatment of:
                    <ce:list id="l0045">
                        <ce:list-item id="u0145">
                            <ce:label>•</ce:label>
                            <ce:para id="p0295">Epilepsy.</ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0150">
                            <ce:label>•</ce:label>
                            <ce:para id="p0300">Acute mania – see page<ce:intra-ref id="ia9550"
                                                                                    xlink:href="pii:B978-0-7234-3863-2.00018-0#s0090">
                                137</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0155">
                            <ce:label>•</ce:label>
                            <ce:para id="p0305">Prophylaxis of bipolar of affective disorder (unlicensed indication) –
                                see page<ce:intra-ref id="ia9155" xlink:href="pii:B978-0-7234-3863-2.00018-0#s0135">
                                    138</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                    Carbamazepine is used in the treatment of:
                    <ce:list id="l0050">
                        <ce:list-item id="u0160">
                            <ce:label>•</ce:label>
                            <ce:para id="p0315">Epilepsy.</ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0165">
                            <ce:label>•</ce:label>
                            <ce:para id="p0320">Prophylaxis of bipolar affective disorder (not first line) – see page
                                <ce:intra-ref id="ia9160" xlink:href="pii:B978-0-7234-3863-2.00018-0#s0135">
                                    138</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                    Lamotrigine is used in the treatment of:
                    <ce:list id="l0055">
                        <ce:list-item id="u0180">
                            <ce:label>•</ce:label>
                            <ce:para id="p0340">Epilepsy.</ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0185">
                            <ce:label>•</ce:label>
                            <ce:para id="p0345">Prophylaxis of depressive episodes in bipolar affective disorder – see
                                page<ce:intra-ref id="ia9175" xlink:href="pii:B978-0-7234-3863-2.00018-0#s0135">
                                    138</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                    <ce:display>
                        <ce:textbox role="alt0" id="b0025">
                            <ce:textbox-head>
                                <ce:title>HINTS AND TIPS</ce:title>
                            </ce:textbox-head>
                            <ce:textbox-body>
                                <ce:sections>
                                    <ce:para id="p0350">Valproate is available in formulations as sodium valproate,
                                        valproic acid and semisodium valproate (Depakote®), which comprises equimolar
                                        amounts of sodium valproate and valproic acid. Different formulations have
                                        different equivalent doses, so prescribe by brand.
                                    </ce:para>
                                </ce:sections>
                            </ce:textbox-body>
                        </ce:textbox>
                    </ce:display>
                </ce:para>
            </ce:section>
            <ce:section id="s0075">
                <ce:section-title id="st0080">Side-effects and contraindications</ce:section-title>
                <ce:section id="s0080">
                    <ce:section-title id="st0085">Lithium</ce:section-title>
                    <ce:para id="p0355">Lithium has a narrow therapeutic window between non-therapeutic and toxic blood
                        levels. Lower levels can be toxic in older patients.
                        <ce:list id="l0060">
                            <ce:list-item id="u0190">
                                <ce:label>•</ce:label>
                                <ce:para id="p0360">Therapeutic levels: 0.5–1.0<ce:hsp sp="0.25"/>mmol/L.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0195">
                                <ce:label>•</ce:label>
                                <ce:para id="p0365">Toxic levels: &gt;<ce:hsp sp="0.10"/>1.5<ce:hsp sp="0.25"/>mmol/L.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0200">
                                <ce:label>•</ce:label>
                                <ce:para id="p0370">Dangerously toxic levels: &gt;<ce:hsp sp="0.10"/>2<ce:hsp
                                        sp="0.25"/>mmol/L.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                        Lithium is only taken orally and is excreted almost entirely by the kidneys. Clearance of
                        lithium is decreased with renal impairment (e.g. in older adults, dehydration) and sodium
                        depletion. Certain drugs such as diuretics (especially thiazides), nonsteroidal
                        anti-inflammatory drugs (NSAIDs), and ACE-inhibitors can also increase lithium levels and should
                        ideally be avoided or prescribed with utmost caution. Furthermore, antipsychotics may
                        synergistically increase lithium-induced neurotoxicity; this is important as lithium and
                        antipsychotics are often coadministered in acute mania.
                        <ce:cross-ref refid="f0035">Figure 2.6</ce:cross-ref>
                        <ce:float-anchor refid="f0035"/>
                        summarizes the side-effects and signs of toxicity of lithium.
                    </ce:para>
                    <ce:para id="p0380">It follows that the following investigations are needed prior to initiating
                        therapy:
                        <ce:list id="l0065">
                            <ce:list-item id="u0205">
                                <ce:label>•</ce:label>
                                <ce:para id="p0385">Full blood count.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0210">
                                <ce:label>•</ce:label>
                                <ce:para id="p0390">Renal function and electrolytes.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0215">
                                <ce:label>•</ce:label>
                                <ce:para id="p0395">Thyroid function.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0220">
                                <ce:label>•</ce:label>
                                <ce:para id="p0400">Pregnancy test (in women of childbearing age).</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0225">
                                <ce:label>•</ce:label>
                                <ce:para id="p0405">Electrocardiogram (ECG) (if cardiac risk factors).</ce:para>
                            </ce:list-item>
                        </ce:list>
                        Blood levels are monitored weekly after starting treatment until a therapeutic level has been
                        stable for 4 weeks. Lithium blood levels should then be monitored every 3 months; renal function
                        every 6 months; and thyroid function every 12 months.
                    </ce:para>
                    <ce:para id="p0415">Contraindications/cautions: pregnancy, breastfeeding (see page<ce:intra-ref
                            id="ia9060" xlink:href="pii:B978-0-7234-3863-2.00024-6#u0050">168</ce:intra-ref>), impaired
                        renal function, thyroid disease, cardiac conditions, neurological conditions (e.g. Parkinson's
                        or Huntington's disease).
                        <ce:display>
                            <ce:textbox role="alt0" id="b0030">
                                <ce:textbox-head>
                                    <ce:title>HINTS AND TIPS</ce:title>
                                </ce:textbox-head>
                                <ce:textbox-body>
                                    <ce:sections>
                                        <ce:para id="p0420">Mood stabilizers have potentially serious pharmacokinetic
                                            and pharmacodynamic interactions with many other drugs. Therefore, before
                                            prescribing new medication for patients on mood stabilizers, check a drug
                                            interactions reference (e.g. Appendix 1 in the British National Formulary
                                            (BNF)).
                                        </ce:para>
                                    </ce:sections>
                                </ce:textbox-body>
                            </ce:textbox>
                        </ce:display>
                    </ce:para>
                </ce:section>
                <ce:section id="s0085">
                    <ce:section-title id="st0090">Sodium valproate, carbamazepine and lamotrigine</ce:section-title>
                    <ce:para id="p0425">
                        <ce:cross-ref refid="f0040">Figure 2.7</ce:cross-ref>
                        <ce:float-anchor refid="f0040"/>
                        summarizes the side-effects of carbamazepine, valproate and lamotrigine. It is important to
                        check liver and haematological functions prior to, and soon after, starting valproate or
                        carbamazepine due to the risk of serious blood and hepatic disorders. Lamotrigine can, rarely,
                        be associated with Stevens–Johnson syndrome, particularly in the first 8 weeks. Patients should
                        be advised to stop if there is development of a rash, and reintroduction of lamotrigine at a
                        later date considered only by a specialist.
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0090">
            <ce:section-title id="st0095">ANTIPSYCHOTICS</ce:section-title>
            <ce:section id="s0095">
                <ce:section-title id="st0100">History and classification</ce:section-title>
                <ce:para id="p0430">Antipsychotics or neuroleptics (originally known as ‘major tranquillizers’) appeared
                    in the early 1950s with the introduction of the phenothiazine chlorpromazine. A number of
                    antipsychotics with a similar pharmacodynamic action soon followed, e.g. the butyrophenone
                    haloperidol in the 1960s. Their ability to treat psychotic symptoms had a profound impact on
                    psychiatry, accelerating the movement of patients out of asylums and into the community. However,
                    serious motor side-effects (extrapyramidal side-effects (EPSE)), soon became apparent with all these
                    drugs.
                </ce:para>
                <ce:para id="p0435">Clozapine was the first antipsychotic with fewer EPSE, and thus was termed
                    ‘atypical’. It led to the introduction of several other atypical (or ‘second generation’)
                    antipsychotics, including risperidone, olanzapine and quetiapine. The older antipsychotics such as
                    haloperidol and chlorpromazine became known as the conventional, ‘first generation’, or ‘typical’
                    antipsychotics. However, this distinction is increasingly viewed as artificial – all antipsychotics
                    can induce extrapyramidal motor side-effects if given at high enough doses. Clozapine is the only
                    ‘true’ atypical antipsychotic in that it has a distinct receptor binding profile and can be
                    effective in two-thirds of the patients for whom other antipsychotics have failed.
                    <ce:cross-ref refid="f0045">Figure 2.8</ce:cross-ref>
                    <ce:float-anchor refid="f0045"/>
                    lists common antipsychotics.
                </ce:para>
            </ce:section>
            <ce:section id="s0100">
                <ce:section-title id="st0105">Mechanism of action and side-effects</ce:section-title>
                <ce:para id="p0440">The primary mechanism of action of all antipsychotics, with the possible exception
                    of clozapine, is antagonism of dopamine D
                    <ce:inf>2</ce:inf>
                    receptors in the mesolimbic dopamine pathway. Clozapine is a comparatively weak D
                    <ce:inf>2</ce:inf>
                    antagonist but has a high affinity for serotonin type 2 receptors (5-HT<ce:inf>2</ce:inf>) and D
                    <ce:inf>4</ce:inf>
                    receptors, among many other receptor targets. Most second generation antipsychotics also block 5-HT
                    <ce:inf>2</ce:inf>
                    receptors.
                </ce:para>
                <ce:para id="p0445">Unfortunately, blockade of dopamine D
                    <ce:inf>2</ce:inf>
                    receptors occurs throughout the brain, resulting in diverse side-effects. In addition,
                    antipsychotics also cause side-effects by blocking muscarinic, histaminergic and α-adrenergic
                    receptors (as do TCAs).
                    <ce:cross-ref refid="f0050">Figure 2.9</ce:cross-ref>
                    <ce:float-anchor refid="f0050"/>
                    summarizes both the useful and troublesome clinical effects of D<ce:inf>2</ce:inf>-receptor
                    antagonism as well as the side-effects caused by the blockage of other receptors. Learn this table
                    well; these effects are often asked for in exams.
                </ce:para>
                <ce:para id="p0450">The risk of metabolic syndrome (obesity, diabetes, hypertension and dyslipidaemia)
                    is particularly high with clozapine and other second generation antipsychotics. Metabolic syndrome
                    is associated with increased cardiovascular mortality so it is important to monitor and manage the
                    components of this syndrome.
                </ce:para>
                <ce:para id="p0455">Clozapine is associated with some rare serious side-effects such as agranulocytosis,
                    myocarditis and cardiomyopathy which mean it is reserved for treatment-resistant cases.
                </ce:para>
                <ce:para id="p0460">Contraindications/cautions: severely reduced consciousness level (sedating),
                    phaeochromocytoma, Parkinson's disease (can exacerbate), epilepsy (seizure threshold lowered),
                    cardiac disease (can induce arrhythmias – consider baseline ECG) and metabolic syndrome). Clozapine
                    should not be re-prescribed to someone with a history of agranulocytosis.
                    <ce:display>
                        <ce:textbox role="alt0" id="b0035">
                            <ce:textbox-head>
                                <ce:title>HINTS AND TIPS</ce:title>
                            </ce:textbox-head>
                            <ce:textbox-body>
                                <ce:sections>
                                    <ce:para id="p0465">If you can remember the side-effects of tricyclic
                                        antidepressants you can remember many of the side-effects of antipsychotics as
                                        both are multi-receptor blockers. Both groups are anticholinergic (dry mouth,
                                        constipation, blurred vision, urinary retention), anti-adrenergic (postural
                                        hypotension) and anti-histaminergic (sedation, weight gain).
                                    </ce:para>
                                </ce:sections>
                            </ce:textbox-body>
                        </ce:textbox>
                    </ce:display>
                    <ce:display>
                        <ce:textbox role="alt0" id="b0040">
                            <ce:textbox-head>
                                <ce:title>HINTS AND TIPS</ce:title>
                            </ce:textbox-head>
                            <ce:textbox-body>
                                <ce:sections>
                                    <ce:para id="p0470">The extrapyramidal side-effects (EPSE) of parkinsonian motor
                                        symptoms and acute dystonia are due to a relative deficiency of dopamine and an
                                        excess of acetylcholine induced by dopamine antagonism in the nigrostriatal
                                        pathway. This is why anticholinergic drugs are effective treatments.
                                    </ce:para>
                                </ce:sections>
                            </ce:textbox-body>
                        </ce:textbox>
                    </ce:display>
                </ce:para>
                <ce:para id="p0475">
                    <ce:cross-ref refid="f0055">Figure 2.10</ce:cross-ref>
                    <ce:float-anchor refid="f0055"/>
                    summarizes the antipsychotic-induced extrapyramidal side-effects and treatment. See also
                    <ce:cross-ref refid="f0060">Figure 2.11</ce:cross-ref>.
                </ce:para>
                <ce:para id="p0480">Certain antipsychotics are available in a slow-release form, as an intramuscular
                    depot preparation that can be administered every 1–4 weeks, e.g. flupentixol (Depixol®),
                    zuclopenthixol (Clopixol®). They are used for patients who are poorly concordant with oral therapy.
                    <ce:display>
                        <ce:textbox role="alt0" id="b0045">
                            <ce:textbox-head>
                                <ce:title>HINTS AND TIPS</ce:title>
                            </ce:textbox-head>
                            <ce:textbox-body>
                                <ce:sections>
                                    <ce:para id="p0485">Clozapine is a very effective antipsychotic but, due to the
                                        life-threatening risk of bone marrow suppression with agranulocytosis (0.8% of
                                        patients), is only used in treatment-resistant schizophrenia. Patients should be
                                        registered with a clozapine monitoring service and have a full blood count (FBC)
                                        prior to starting treatment. This is followed by weekly FBCs for several weeks,
                                        followed by monthly FBCs for the duration of treatment. With monitoring,
                                        fatalities from agranulocytosis are very rare (less than 1 in 5000 patients on
                                        clozapine).
                                    </ce:para>
                                </ce:sections>
                            </ce:textbox-body>
                        </ce:textbox>
                    </ce:display>
                </ce:para>
            </ce:section>
            <ce:section id="s0105">
                <ce:section-title id="st0110">Indications</ce:section-title>
                <ce:section id="s0110">
                    <ce:section-title id="st0115">Psychiatric indications</ce:section-title>
                    <ce:para id="p0490">
                        <ce:list id="l0070">
                            <ce:list-item id="u0230">
                                <ce:label>•</ce:label>
                                <ce:para id="p0495">Schizophrenia, schizoaffective disorder, delusional disorder – see
                                    page<ce:intra-ref id="ia9165" xlink:href="pii:B978-0-7234-3863-2.00019-2#b0015">
                                        143</ce:intra-ref>.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0235">
                                <ce:label>•</ce:label>
                                <ce:para id="p0500">Depression or mania with psychotic features – see page
                                    <ce:intra-ref id="ia9145" xlink:href="pii:B978-0-7234-3863-2.00018-0#f0025">136
                                    </ce:intra-ref>
                                    and page<ce:intra-ref id="ia9235" xlink:href="pii:B978-0-7234-3863-2.00018-0#s0090">
                                        137</ce:intra-ref>.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0240">
                                <ce:label>•</ce:label>
                                <ce:para id="p0505">Psychotic episodes secondary to a medical condition or psychoactive
                                    substance use.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0245">
                                <ce:label>•</ce:label>
                                <ce:para id="p0510">Delirium – see page
                                    <ce:intra-ref id="ia9070" xlink:href="pii:B978-0-7234-3863-2.00025-8#s0110">178
                                    </ce:intra-ref>
                                    (caution in alcohol withdrawal as lowers seizure threshold).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0250">
                                <ce:label>•</ce:label>
                                <ce:para id="p0515">Behavioural disturbance in dementia – see page
                                    <ce:intra-ref id="ia9075" xlink:href="pii:B978-0-7234-3863-2.00025-8#u0155">177
                                    </ce:intra-ref>
                                    (caution as increased risk of cerebrovascular accident).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0255">
                                <ce:label>•</ce:label>
                                <ce:para id="p0520">Severe agitation, anxiety and violent or impulsive behaviour – see
                                    page<ce:intra-ref id="ia9265" xlink:href="pii:B978-0-7234-3863-2.00019-2#u0125">
                                        145</ce:intra-ref>.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0115">
                    <ce:section-title id="st0120">Non-psychiatric indications</ce:section-title>
                    <ce:para id="p0525">
                        <ce:list id="l0075">
                            <ce:list-item id="u0260">
                                <ce:label>•</ce:label>
                                <ce:para id="p0530">Motor tics (Gilles de la Tourette's syndrome) – see page
                                    <ce:intra-ref id="ia9080" xlink:href="pii:B978-0-7234-3863-2.00027-1#s0145">
                                        191</ce:intra-ref>.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0265">
                                <ce:label>•</ce:label>
                                <ce:para id="p0535">Nausea and vomiting, e.g. prochlorperazine.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0270">
                                <ce:label>•</ce:label>
                                <ce:para id="p0540">Intractable hiccups and pruritus, e.g. chlorpromazine,
                                    haloperidol.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0120">
            <ce:section-title id="st0125">ANXIOLYTIC AND HYPNOTIC DRUGS</ce:section-title>
            <ce:para id="p0545">A hypnotic drug is one that induces sleep. An anxiolytic or sedative drug is one that
                reduces anxiety. This differentiation is not particularly helpful as anxiolytic drugs can induce sleep
                when given in higher doses and hypnotics can have a calming effect when given in lower doses, e.g. the
                benzodiazepines, which are anxiolytic in low doses and hypnotic in high doses. All of these drugs can
                result in tolerance, dependence and withdrawal symptoms. Furthermore, their effects, when used in
                combination or with alcohol, are additive. The most important drugs in this group are the
                benzodiazepines and ‘Z drugs” (zopiclone, zolpidem and zaleplon), which have very similar actions and
                indications.
                <ce:display>
                    <ce:textbox role="alt0" id="b0050">
                        <ce:textbox-head>
                            <ce:title>HINTS AND TIPS</ce:title>
                        </ce:textbox-head>
                        <ce:textbox-body>
                            <ce:sections>
                                <ce:para id="p0550">In the past, the antipsychotics have been referred to as the ‘major
                                    tranquillizers’ and the anxiolytics as the ‘minor tranquillizers’. This is
                                    misleading because: (1) these drugs are not pharmacologically related; (2) the
                                    antipsychotics do far more than just tranquillize; and (3) the effect and use of
                                    anxiolytics is in no way minor.
                                </ce:para>
                            </ce:sections>
                        </ce:textbox-body>
                    </ce:textbox>
                </ce:display>
            </ce:para>
            <ce:section id="s0125">
                <ce:section-title id="st0130">History</ce:section-title>
                <ce:para id="p0555">In the 1960s the benzodiazepines replaced the often abused barbiturates as the drugs
                    of choice for the treatment of anxiety and insomnia. However, this initial enthusiasm was tempered
                    by the observations that they were associated with serious dependence and withdrawal syndromes, and
                    had gained a market as drugs of abuse. Z drugs were introduced in the 1990s and initially thought to
                    be less likely to cause dependence – this is not true. Today, benzodiazepines and Z drugs are
                    recognized as highly effective and relatively safe drugs when prescribed judiciously, for short
                    periods, and with good patient education.
                </ce:para>
            </ce:section>
            <ce:section id="s0130">
                <ce:section-title id="st0135">Classification</ce:section-title>
                <ce:para id="p0560">From a clinical perspective, it is important to classify benzodiazepines and Z drugs
                    according to their strength, their length of action and their routes of administration.
                    <ce:cross-ref refid="f0065">Figure 2.12</ce:cross-ref>
                    <ce:float-anchor refid="f0065"/>
                    summarizes these qualities in some common drugs.
                </ce:para>
            </ce:section>
            <ce:section id="s0135">
                <ce:section-title id="st0140">Mechanism of action</ce:section-title>
                <ce:para id="p0565">Benzodiazepines potentiate the action of GABA (γ-aminobutyric acid), the main
                    inhibitory neurotransmitter in the brain. They bind to specific benzodiazepine receptors on the GABA
                    <ce:inf>A</ce:inf>
                    receptor complex, which results in an increased affinity of the complex for GABA, and so an
                    increased flow of chloride ions into the cell. This hyperpolarizes the post-synaptic membrane and
                    reduces neuronal excitability. Z drugs act at a different site on the benzodiazepine receptor in the
                    GABA
                    <ce:inf>A</ce:inf>
                    receptor complex, also potentiating chloride entry.
                </ce:para>
            </ce:section>
            <ce:section id="s0140">
                <ce:section-title id="st0145">Indications of benzodiazepines</ce:section-title>
                <ce:para id="p0570">
                    <ce:list id="l0080">
                        <ce:list-item id="u0275">
                            <ce:label>•</ce:label>
                            <ce:para id="p0575">Insomnia, especially short-acting benzodiazepines (short-term use) – see
                                page<ce:intra-ref id="ia9085" xlink:href="pii:B978-0-7234-3863-2.00030-1#f0015">
                                    203</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0280">
                            <ce:label>•</ce:label>
                            <ce:para id="p0580">Anxiety disorders – see page<ce:intra-ref id="ia9690"
                                                                                          xlink:href="pii:B978-0-7234-3863-2.00020-9#s0045">
                                150</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0285">
                            <ce:label>•</ce:label>
                            <ce:para id="p0585">Alcohol withdrawal, especially chlordiazepoxide – see page<ce:intra-ref
                                    id="ia9095" xlink:href="pii:B978-0-7234-3863-2.00021-0#u0115">154</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0290">
                            <ce:label>•</ce:label>
                            <ce:para id="p0590">Akathisia – see<ce:cross-ref refid="f0055">Figure 2.10</ce:cross-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0295">
                            <ce:label>•</ce:label>
                            <ce:para id="p0595">Acute mania or psychosis (sedation) – see page<ce:intra-ref id="ia9650"
                                                                                                            xlink:href="pii:B978-0-7234-3863-2.00018-0#s0090">
                                137</ce:intra-ref>,<ce:intra-ref id="ia9365"
                                                                 xlink:href="pii:B978-0-7234-3863-2.00019-2#b0015">143
                                and page 145</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0300">
                            <ce:label>•</ce:label>
                            <ce:para id="p0600">Other: epilepsy prophylaxis, seizures, muscle spasm (diazepam),
                                anaesthetic premedication.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                </ce:para>
            </ce:section>
            <ce:section id="s0145">
                <ce:section-title id="st0150">Indications of Z drugs</ce:section-title>
                <ce:para id="p0605">
                    <ce:list id="l0085">
                        <ce:list-item id="u0305">
                            <ce:label>•</ce:label>
                            <ce:para id="p0610">Insomnia (short-term use) – see page<ce:intra-ref id="ia9100"
                                                                                                  xlink:href="pii:B978-0-7234-3863-2.00030-1#f0015">
                                203</ce:intra-ref>.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                </ce:para>
            </ce:section>
            <ce:section id="s0150">
                <ce:section-title id="st0155">Side-effects of benzodiazepines and Z drugs</ce:section-title>
                <ce:para id="p0615">
                    <ce:list id="l0090">
                        <ce:list-item id="u0310">
                            <ce:label>•</ce:label>
                            <ce:para id="p0620">Risk of developing dependence, especially with prolonged use and shorter
                                acting drugs.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0315">
                            <ce:label>•</ce:label>
                            <ce:para id="p0625">Patients should be warned about the potential dangers of driving or
                                operating machinery due to drowsiness, ataxia and reduced motor coordination.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0320">
                            <ce:label>•</ce:label>
                            <ce:para id="p0630">Use with great caution in older adults where drowsiness, confusion and
                                ataxia can precipitate falls or delirium.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0325">
                            <ce:label>•</ce:label>
                            <ce:para id="p0635">Use with caution in patients with chronic respiratory disease (e.g.
                                COPD, sleep apnoea) as they may depress respiration.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                    <ce:display>
                        <ce:textbox role="alt0" id="b0055">
                            <ce:textbox-head>
                                <ce:title>HINTS AND TIPS</ce:title>
                            </ce:textbox-head>
                            <ce:textbox-body>
                                <ce:sections>
                                    <ce:para id="p0640">Benzodiazepines or Z drugs (zopiclone, zolpidem and zaleplon),
                                        are seldom fatal in overdose if taken alone, but can be when taken in
                                        combination with other sedatives. Flumazenil is an antagonist at the
                                        benzodiazepine receptor, and can reverse the effects of both benzodiazepines and
                                        Z drugs.
                                    </ce:para>
                                </ce:sections>
                            </ce:textbox-body>
                        </ce:textbox>
                    </ce:display>
                    <ce:display>
                        <ce:textbox role="alt0" id="b0060">
                            <ce:textbox-head>
                                <ce:title>HINTS AND TIPS</ce:title>
                            </ce:textbox-head>
                            <ce:textbox-body>
                                <ce:sections>
                                    <ce:para id="p0645">Alcohol, opiates, barbiturates, tricyclic antidepressants,
                                        antihistamines and other sedatives may all enhance the effects of
                                        benzodiazepines and Z drugs; therefore, moderate doses of benzodiazepines in
                                        combination with some of these substances can result in respiratory depression.
                                    </ce:para>
                                </ce:sections>
                            </ce:textbox-body>
                        </ce:textbox>
                    </ce:display>
                </ce:para>
            </ce:section>
            <ce:section id="s0155">
                <ce:section-title id="st0160">Other hypnotic and anxiolytic agents</ce:section-title>
                <ce:para id="p0650">
                    <ce:list id="l0095">
                        <ce:list-item id="u0330">
                            <ce:label>•</ce:label>
                            <ce:para id="p0655">Buspirone is a 5-HT
                                <ce:inf>1A</ce:inf>
                                receptor agonist that is used to treat generalized anxiety disorder. It is unrelated to
                                the benzodiazepines, does not have hypnotic, anticonvulsant or muscle relaxant
                                properties, and is not associated with dependence or abuse. Response to treatment may
                                take up to 2 weeks, unlike the benzodiazepines which have an immediate anxiolytic
                                effect.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0335">
                            <ce:label>•</ce:label>
                            <ce:para id="p0660">Sedating antihistamines (e.g. diphenhydramine (Nytol®)) are available
                                for insomnia without a prescription. Unfortunately, their long duration of action may
                                lead to drowsiness the following day.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                </ce:para>
            </ce:section>
        </ce:section>
        <ce:section id="s0160">
            <ce:section-title id="st0165">OTHER DRUGS USED IN PSYCHIATRY</ce:section-title>
            <ce:para id="p0665">
                <ce:list id="l0100">
                    <ce:list-item id="u0340">
                        <ce:para id="p0670"><ce:bold>Alcohol dependence</ce:bold>: acamprosate, disulfiram – see page
                            <ce:intra-ref id="ia9605" xlink:href="pii:B978-0-7234-3863-2.00022-2#b0010">
                                155</ce:intra-ref>.
                        </ce:para>
                    </ce:list-item>
                    <ce:list-item id="u0345">
                        <ce:para id="p0675"><ce:bold>Opiate dependence</ce:bold>: methadone, buprenorphine, lofexidine,
                            naltrexone – see page<ce:intra-ref id="ia9710"
                                                               xlink:href="pii:B978-0-7234-3863-2.00021-0#f0020">
                                157</ce:intra-ref>.
                        </ce:para>
                    </ce:list-item>
                    <ce:list-item id="u0350">
                        <ce:para id="p0680"><ce:bold>Dementia</ce:bold>: cholinesterase inhibitors (donepezil,
                            rivastigmine, galantamine), memantine – see page<ce:intra-ref id="ia9115"
                                                                                          xlink:href="pii:B978-0-7234-3863-2.00025-8#u0155">
                                177</ce:intra-ref>.
                        </ce:para>
                    </ce:list-item>
                    <ce:list-item id="u0355">
                        <ce:para id="p0685"><ce:bold>Psychostimulants</ce:bold>: methylphenidate, dexamfetamine – see
                            page<ce:intra-ref id="ia9220" xlink:href="pii:B978-0-7234-3863-2.00027-1#o0045">189 and page
                                204</ce:intra-ref>.
                        </ce:para>
                    </ce:list-item>
                    <ce:list-item id="u0360">
                        <ce:para id="p0690"><ce:bold>Generalized anxiety disorder</ce:bold>: pregabalin – see page
                            <ce:intra-ref id="ia9590" xlink:href="pii:B978-0-7234-3863-2.00020-9#s0045">
                                150</ce:intra-ref>.
                        </ce:para>
                    </ce:list-item>
                </ce:list>
            </ce:para>
        </ce:section>
        <ce:section id="s0165">
            <ce:section-title id="st0170">ELECTROCONVULSIVE THERAPY</ce:section-title>
            <ce:section id="s0170">
                <ce:section-title id="st0175">History</ce:section-title>
                <ce:para id="p0695">The possibility that seizures could improve psychiatric symptoms arose from the
                    observation that convulsions appeared to lead to an improvement of psychotic symptoms in patients
                    with comorbid epilepsy and schizophrenia. This led to seizures being induced pharmacologically with
                    intramuscular camphor in the early 1930s. An electric stimulus was later discovered to be an
                    effective way of inducing seizures, although it proved to be a crude and often dangerous procedure
                    without modern-day anaesthetic induction agents and muscle relaxants. Today, ECT is a safe and often
                    life-saving treatment for patients with serious mental illness. It is the most effective treatment
                    known for severe depression.
                </ce:para>
            </ce:section>
            <ce:section id="s0175">
                <ce:section-title id="st0180">Indications</ce:section-title>
                <ce:para id="p0700">ECT is predominantly used for depression, and can be particularly effective in older
                    adults. Although antidepressants are usually tried first, ECT is considered for the following
                    features of depression:
                    <ce:list id="l0105">
                        <ce:list-item id="u0365">
                            <ce:label>•</ce:label>
                            <ce:para id="p0705">Life-threatening poor fluid intake.</ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0370">
                            <ce:label>•</ce:label>
                            <ce:para id="p0710">Strong suicidal intent.</ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0375">
                            <ce:label>•</ce:label>
                            <ce:para id="p0715">Psychotic features or stupor.</ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0380">
                            <ce:label>•</ce:label>
                            <ce:para id="p0720">Antidepressants are ineffective or not tolerated.</ce:para>
                        </ce:list-item>
                    </ce:list>
                </ce:para>
                <ce:para id="p0725">Although ECT may precipitate a manic episode in patients with bipolar affective
                    disorder, it is an effective treatment for established mania. ECT is also an effective treatment for
                    certain types of schizophrenia, specifically catatonic states, positive psychotic symptoms and
                    schizoaffective disorder. ECT is also used for puerperal psychosis (see<ce:intra-ref
                            xlink:href="pii:B978-0-7234-3863-2.00024-6" id="ia0010">Ch. 24</ce:intra-ref>) with
                    prominent mood symptoms or severe postnatal depression where a rapid improvement is necessary to
                    reunite the mother with her baby.
                </ce:para>
            </ce:section>
            <ce:section id="s0180">
                <ce:section-title id="st0185">Administration and mechanism of action</ce:section-title>
                <ce:para id="p0730">ECT is administered 2–3 times per week. Most patients need between 4 and 12
                    treatments. An anaesthetist administers a short-acting induction agent and muscle relaxant that
                    ensure about 5 minutes of general anaesthesia. During this time, a psychiatrist applies two
                    electrodes to the patient's scalp, in a bilateral or unilateral placement, and delivers an electric
                    current of sufficient charge to effect a generalized seizure of at least 15 seconds in duration.
                </ce:para>
                <ce:para id="p0735">It is still not clear how ECT works. It causes a release of neurotransmitters as
                    well as hypothalamic and pituitary hormones; it also affects neurotransmitter receptors and second
                    messenger systems, and results in a transient increase in blood–brain barrier permeability.
                </ce:para>
            </ce:section>
            <ce:section id="s0185">
                <ce:section-title id="st0190">Side-effects</ce:section-title>
                <ce:para id="p0740">The mortality rate associated with ECT is the same as that for any minor surgical
                    procedure under general anaesthesia (i.e. around 1 in 100<ce:hsp sp="0.12"/>000). Loss of memory is
                    a common complaint, particularly for events surrounding the ECT. Some patients also report some
                    impairment of autobiographical memory. Unfortunately, studies that examine the long-term effects of
                    ECT are difficult to perform. Memory impairment can be reduced by unilateral electrode placement (as
                    opposed to bilateral).
                </ce:para>
                <ce:para id="p0745">Minor complaints such as confusion, headache, nausea and muscle pains are
                    experienced by 80% of patients. Anaesthetic complications (e.g. arrhythmias, aspiration) can be
                    reduced by good preoperative assessment. Prolonged seizures may occur, especially in patients who
                    are on drugs that lower the seizure threshold (e.g. antidepressants and antipsychotics). In
                    contrast, benzodiazepines increase the seizure threshold, making it more difficult to induce a
                    seizure of adequate length.
                </ce:para>
            </ce:section>
            <ce:section id="s0190">
                <ce:section-title id="st0195">Contraindications</ce:section-title>
                <ce:para id="p0750">There are no absolute contraindications to ECT. Relative contraindications include:
                    <ce:list id="l0110">
                        <ce:list-item id="u0385">
                            <ce:label>•</ce:label>
                            <ce:para id="p0755">Heart disease (recent myocardial infarction, heart failure, ischaemic
                                heart disease).
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0390">
                            <ce:label>•</ce:label>
                            <ce:para id="p0760">Raised intracranial pressure.</ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0395">
                            <ce:label>•</ce:label>
                            <ce:para id="p0765">Risk of cerebral bleeding (hypertension, recent stroke).</ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0425">
                            <ce:label>•</ce:label>
                            <ce:para id="p0770">Poor anaesthetic risk.</ce:para>
                        </ce:list-item>
                    </ce:list>
                </ce:para>
            </ce:section>
        </ce:section>
    </ce:sections>
</chapter>